Figure 5.

[¹⁸F]FPIA uptake in relation to tumor proliferation and lipid metabolism-associated proteins in subcutaneous HSJD-GBM-001 and U87 glioma xenografts. Tumor proliferation (Ki-67) and the expression of lipid metabolism-associated proteins (CPT1, SLC22A2, SLC22A5, SLS25A20) were assessed using immunohistochemistry. (a) Representative images of marker expression in HSJD-GBM-001 tumors (50 μm), (b) Correlation between [¹⁸F]FPIA tumor uptake and marker expression in both HSJD-GBM-001 and U87 tumors, (c) Tumor proliferation and lipid metabolism-associated protein expression in response to etomoxir treatment were assessed. Treatment with etomoxir significantly decreased Ki-67 and increased CPT1 expression in HSJD-GBM-001 tumors (* p < 0.05 and p = 0.0001, 2-way ANOVA, respectively), and decreased SLC22A5 expression in U87 tumors (* p < 0.05, 2-way ANOVA).